Regeneron (REGN) Withdraws sBLA for Libtayo in Cervical Cancer
1 min read
Regeneron (REGN) Withdraws sBLA for Libtayo in Cervical Cancer
Regeneron (REGN) as well as companion Sanofi willingly take out the supplemental biologics certify application for Libtayo in second-line therapy of innovative cervical cancer.Read More …